Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer

NCT00089310 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Diagnostic procedures such as sentinel lymph node mapping may improve the ability to detect cancer that has spread to the lymph nodes. PURPOSE: This clinical trial is studying how well sentinel lymph node mapping works in detecting cancer that has spread to the lymph nodes in patients who are undergoing surgery for stage I non-small cell lung cancer.

Conditions Studied

Interventions

  • RADIATION technetium-99

Study Locations (12)

New York

  • Roswell Park Cancer Institute — Buffalo
  • Elmhurst Hospital Center — Elmhurst
  • Queens Cancer Center of Queens Hospital — Jamaica
  • Mount Sinai Medical Center — New York
  • SUNY Upstate Medical University Hospital — Syracuse

Delaware

  • Beebe Medical Center — Lewes
  • CCOP - Christiana Care Health Services — Newark

Illinois

  • Evanston Northwestern Healthcare - Evanston Hospital — Evanston

Missouri

  • Veterans Affairs Medical Center - Columbia (Truman Memorial) — Columbia

New Jersey

  • Cancer Institute of New Jersey at Cooper - Voorhees — Voorhees Township

North Carolina

  • Veterans Affairs Medical Center - Asheville — Asheville

Ohio

  • Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University — Columbus

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2004-09
Est. Completion 2009-04
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00089310

The ClinicalTrials.gov registry entry for NCT00089310 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which technetium-99 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00089310 reports 12 study locations spanning 7 distinct geographic areas — top geographies include New York, Delaware, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00089310 about?

NCT00089310 is a clinical study titled "Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer". RATIONALE: Diagnostic procedures such as sentinel lymph node mapping may improve the ability to detect cancer that has spread to the lymph nodes. PURPOSE: This clinical trial is studying how well sentinel lymph node mapping works in detecting cancer that has spread to the lymph nodes in patients wh...

What is the current status of trial NCT00089310?

This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2004-09. Estimated completion is 2009-04.

What conditions does trial NCT00089310 study?

This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00089310?

The interventions under investigation include: technetium-99 (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00089310?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00089310 being conducted?

This trial has 12 study locations across Delaware, Illinois, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial